Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ILV-094 Administered IV and One Dose of SC Administered to Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2009
At a glance
- Drugs Fezakinumab (Primary)
- Indications Psoriasis; Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- 14 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jul 2009 Actual end date (Feb 2008) added as reported by ClinicalTrials.gov.
- 14 Jul 2009 Planned patient number (56) added as reported by ClinicalTrials.gov.